Myriad Genetics Stock Price, News & Analysis (NASDAQ:MYGN)

$33.14 +0.44 (+1.35 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$33.14
Today's Range$32.13 - $33.25
52-Week Range$17.50 - $41.57
Volume392,166 shs
Average Volume822,533 shs
Market Capitalization$2.35 billion
P/E Ratio18.01
Dividend YieldN/A
Beta0.32

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics logoMyriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Diagnostic & Testing Equipment
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:MYGN
CUSIP62855J10
Phone+1-801-5843600

Debt

Debt-to-Equity Ratio0.05%
Current Ratio2.05%
Quick Ratio1.81%

Price-To-Earnings

Trailing P/E Ratio18.0108695652174
Forward P/E Ratio28.82
P/E Growth2.31

Sales & Book Value

Annual Sales$771.40 million
Price / Sales3.00
Cash Flow$1.80 per share
Price / Cash18.45
Book Value$13.09 per share
Price / Book2.53

Profitability

Trailing EPS$1.84
Net Income$21.80 million
Net Margins16.67%
Return on Equity9.59%
Return on Assets6.42%

Miscellaneous

Employees2,400
Outstanding Shares69,850,000

Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Tuesday, February, 6th. The company reported $0.31 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.24 by $0.07. The business had revenue of $194 million for the quarter, compared to analysts' expectations of $188.72 million. Myriad Genetics had a return on equity of 9.59% and a net margin of 16.67%. The business's revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.26 earnings per share. View Myriad Genetics' Earnings History.

When will Myriad Genetics make its next earnings announcement?

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Myriad Genetics.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $1.11-1.16 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.05. The company issued revenue guidance of $760-770 million, compared to the consensus revenue estimate of $770.68 million.Myriad Genetics also updated its Q3 guidance to $0.26-0.28 EPS.

Where is Myriad Genetics' stock going? Where will Myriad Genetics' stock price be in 2018?

11 Wall Street analysts have issued 12-month target prices for Myriad Genetics' shares. Their predictions range from $16.00 to $45.00. On average, they anticipate Myriad Genetics' stock price to reach $30.45 in the next year. View Analyst Ratings for Myriad Genetics.

What are Wall Street analysts saying about Myriad Genetics stock?

Here are some recent quotes from research analysts about Myriad Genetics stock:

  • 1. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018)
  • 2. According to Zacks Investment Research, "Over the past three months, Myriad Genetics has been trading above the broader industry. Of late, the company has been observing strong growth in GeneSight and EndoPredict testing revenues. Myriad Genetics has also been witnessing continued year-over-year growth in Hereditary Cancer volumes with pricing matching expectations. We are also upbeat about the favorable GeneSight test results entailing patients with Generalized Anxiety Disorder. Notably, the FDA’s acceptance of supplementary premarket approval application for BRACAnalysis CDx as a companion diagnostic to olaparib for treating HER2 negative metastatic breast cancer patients buoys optimism. On the flip side, operating margin has been affected by a rise in operating expenses. Currency fluctuations and stiff competition are other major headwinds." (12/15/2017)
  • 3. Cowen Inc analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)

Who are some of Myriad Genetics' key competitors?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:

  • John T. Henderson M.D., Independent Chairman of the Board (Age 73)
  • Mark C. Capone, President, Chief Executive Officer, Director (Age 55)
  • Mark S. Verratti, President-President Assurex Health (Age 47)
  • Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board (Age 85)
  • R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer (Age 46)
  • Alexander Ford, President of Myriad Genetic Laboratories, Inc. (Age 50)
  • Ralph L. McDade Ph.D., President of Myriad RBM, Inc (Age 62)
  • Bernard F. Tobin, President of Crescendo Bioscience, Inc (Age 55)
  • Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary (Age 59)
  • Gary A. King, Executive Vice President - International Operations (Age 61)

Who owns Myriad Genetics stock?

Myriad Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.41%), Acadian Asset Management LLC (3.19%), Frontier Capital Management Co. LLC (2.82%), Wells Fargo & Company MN (1.31%), Bank of New York Mellon Corp (1.23%) and Pinnacle Associates Ltd. (1.02%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Who sold Myriad Genetics stock? Who is selling Myriad Genetics stock?

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Castleark Management LLC, Deutsche Bank AG, Two Sigma Advisers LP, Millennium Management LLC, Bank of Montreal Can, Tieton Capital Management LLC and Credit Agricole S A. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Gary A King, Heinrich Dreismann, John T Henderson, Richard M Marsh and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.

Who bought Myriad Genetics stock? Who is buying Myriad Genetics stock?

Myriad Genetics' stock was purchased by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Acadian Asset Management LLC, Bogle Investment Management L P DE, Caisse DE Depot ET Placement DU Quebec, Robeco Institutional Asset Management B.V., BlackRock Inc., Convergence Investment Partners LLC and APG Asset Management N.V.. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.

How do I buy Myriad Genetics stock?

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of Myriad Genetics stock can currently be purchased for approximately $33.14.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $2.35 billion and generates $771.40 million in revenue each year. The company earns $21.80 million in net income (profit) each year or $1.84 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 S Wakara Way, SALT LAKE CITY, UT 84108-1214, United States. The company can be reached via phone at +1-801-5843600 or via email at [email protected]


MarketBeat Community Rating for Myriad Genetics (MYGN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  469 (Vote Underperform)
Total Votes:  751
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Myriad Genetics (NASDAQ:MYGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.912.001.901.89
Ratings Breakdown: 3 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.45$29.40$26.56$20.38
Price Target Upside: 9.71% downside23.87% downside14.75% downside26.87% downside

Myriad Genetics (NASDAQ:MYGN) Consensus Price Target History

Price Target History for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ:MYGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018BTIG ResearchSet Price TargetBuy$44.00HighView Rating Details
2/7/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$33.00 -> $35.00HighView Rating Details
2/7/2018Morgan StanleyBoost Price TargetUnderweight -> Underweight$26.00 -> $28.00HighView Rating Details
1/29/2018Goldman Sachs GroupInitiated CoverageSell -> Sell$32.00HighView Rating Details
1/22/2018BarclaysBoost Price TargetEqual Weight -> Equal Weight$30.00 -> $35.00LowView Rating Details
1/3/2018StephensSet Price TargetBuy$45.00MediumView Rating Details
11/8/2017Deutsche BankBoost Price TargetHold$28.00 -> $30.00N/AView Rating Details
9/17/2017CowenReiterated RatingHold$25.00LowView Rating Details
8/10/2017Jefferies GroupReiterated RatingHold$21.00 -> $23.00HighView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$22.00LowView Rating Details
6/30/2017JPMorgan Chase & Co.Reiterated RatingUnderweight$16.00LowView Rating Details
2/8/2017Ladenburg Thalmann Financial ServicesUpgradeSell -> NeutralN/AView Rating Details
10/10/2016Bank of AmericaReiterated RatingSellN/AView Rating Details
8/21/2016Wells Fargo & CoUpgradeMarket Perform -> OutperformN/AView Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00N/AView Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00N/AView Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Myriad Genetics (NASDAQ:MYGN) Earnings History and Estimates Chart

Earnings by Quarter for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ MYGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018$0.27N/AView Earnings Details
2/6/2018Q2 2018$0.24$0.31$188.72 million$194.00 millionViewListenView Earnings Details
11/7/2017Q1 2018$0.21$0.26$183.52 million$190.20 millionViewN/AView Earnings Details
8/8/2017Q4 17$0.26$0.30$193.71 million$200.50 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.24$0.27$188.89 million$196.90 millionViewListenView Earnings Details
2/7/2017Q2 2017$0.24$0.26$189.72 million$196.50 millionViewListenView Earnings Details
11/1/2016Q117$0.26$0.23$172.31 million$177.50 millionViewN/AView Earnings Details
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.33$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.60$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
11/2/2010Q1 2011$0.23$0.24ViewN/AView Earnings Details
8/10/2010Q4 2010$0.33$0.39ViewN/AView Earnings Details
5/4/2010Q3 2010$0.38$0.33ViewN/AView Earnings Details
2/2/2010Q2 2010$0.34$0.36ViewN/AView Earnings Details
11/3/2009Q1 2010$0.32$0.31ViewN/AView Earnings Details
8/25/2009Q4 2009$0.23$0.37ViewN/AView Earnings Details
5/4/2009Q3 2009$0.23$0.25ViewN/AView Earnings Details
2/3/2009Q2 2009$0.17$0.22ViewN/AView Earnings Details
11/4/2008Q1 2009$0.07$0.15ViewN/AView Earnings Details
8/19/2008Q4 2008($0.12)$0.70ViewN/AView Earnings Details
5/6/2008Q3 2008($0.05)($0.05)ViewN/AView Earnings Details
2/5/2008Q2 2008($0.08)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Myriad Genetics (NASDAQ:MYGN) Earnings Estimates

2018 EPS Consensus Estimate: $1.00
2019 EPS Consensus Estimate: $1.29
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.19$0.21$0.20
Q2 20183$0.22$0.23$0.23
Q3 20183$0.26$0.28$0.27
Q4 20183$0.30$0.31$0.30
Q1 20193$0.29$0.32$0.31
Q2 20193$0.29$0.34$0.32
Q3 20193$0.30$0.34$0.32
Q4 20193$0.33$0.35$0.34
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Myriad Genetics (NASDAQ:MYGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Myriad Genetics (NASDAQ MYGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ MYGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Richard M MarshVPSell37,654$40.25$1,515,573.50157,648View SEC Filing  
1/18/2018Gary A KingVPSell3,120$38.12$118,934.40125,088View SEC Filing  
1/12/2018Richard M MarshVPSell13,759$36.25$498,763.75136,385View SEC Filing  
12/14/2017Walter Phd GilbertDirectorSell7,500$33.19$248,925.00View SEC Filing  
12/11/2017Heinrich DreismannDirectorSell6,000$33.50$201,000.0033,743View SEC Filing  
11/13/2017Alexander FordInsiderSell3,031$31.64$95,900.84View SEC Filing  
9/1/2017John T HendersonDirectorSell30,000$30.30$909,000.0052,524View SEC Filing  
2/23/2017John T HendersonDirectorBuy6,000$18.66$111,960.0038,524View SEC Filing  
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.0049,493View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00146,026View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.0056,720View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.1940,122View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.0095,640View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.0095,640View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.0012,500View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.008,500View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.0010,000View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.0068,384View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.0080,573View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.3270,737View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.6070,737View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.3070,737View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.0067,543View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.4251,473View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.5851,473View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.0051,473View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.0051,473View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.0018,285View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.8018,285View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.2018,285View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00930View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.0047,609View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.0015,084View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.0026,084View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.0026,084View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.0017,165View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.5048,268View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.002,949View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.0047,609View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88324View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.9617,165View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.002,949View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.0017,165View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18324View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.0048,268View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.0047,609View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.0055,656View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.0047,177View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.0055,656View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Myriad Genetics (NASDAQ MYGN) News Headlines

Source:
DateHeadline
Myriad Genetics Reaches Analyst Target Price - NasdaqMyriad Genetics Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - February 22 at 3:29 PM
NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer - GlobeNewswire (press release)NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer - GlobeNewswire (press release)
globenewswire.com - February 20 at 3:25 PM
NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate CancerNCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer
finance.yahoo.com - February 20 at 8:52 AM
Myriad Genetics (MYGN) PT Raised to $35.00 at Leerink SwannMyriad Genetics (MYGN) PT Raised to $35.00 at Leerink Swann
www.americanbankingnews.com - February 19 at 8:34 PM
Myriad Genetics Banks on Product Launches, Competition Rife - NasdaqMyriad Genetics Banks on Product Launches, Competition Rife - Nasdaq
www.nasdaq.com - February 19 at 3:24 PM
Myriad Genetics Banks on Product Launches, Competition RifeMyriad Genetics Banks on Product Launches, Competition Rife
finance.yahoo.com - February 19 at 3:24 PM
Myriad Genetics, Inc. Forecasted to Earn FY2018 Earnings of $1.15 Per Share (MYGN)Myriad Genetics, Inc. Forecasted to Earn FY2018 Earnings of $1.15 Per Share (MYGN)
www.americanbankingnews.com - February 19 at 5:40 AM
Myriad Genetics (MYGN) Reports Published Data Demonstrates EndoPredict (EPClin) Significantly Outperforms ... - StreetInsider.comMyriad Genetics (MYGN) Reports Published Data Demonstrates EndoPredict (EPClin) Significantly Outperforms ... - StreetInsider.com
www.streetinsider.com - February 17 at 3:28 PM
This Mornings Technical Outlook on Services Stocks -- Myriad Genetics, QIAGEN, WillScot, and H&R Block - PR Newswire (press release)This Morning's Technical Outlook on Services Stocks -- Myriad Genetics, QIAGEN, WillScot, and H&R Block - PR Newswire (press release)
www.prnewswire.com - February 17 at 3:28 PM
Myriad Genetics (MYGN) Reports Published Data Demonstrates EndoPredict (EPClin ...Myriad Genetics (MYGN) Reports Published Data Demonstrates EndoPredict (EPClin ...
www.streetinsider.com - February 16 at 9:18 AM
JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast CancerJAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer
finance.yahoo.com - February 15 at 3:27 PM
Myriad Genetics Positive Study Data May Expand Customer Base - NasdaqMyriad Genetics' Positive Study Data May Expand Customer Base - Nasdaq
www.nasdaq.com - February 13 at 3:16 PM
 Analysts Anticipate Myriad Genetics, Inc. (MYGN) Will Post Quarterly Sales of $188.14 Million Analysts Anticipate Myriad Genetics, Inc. (MYGN) Will Post Quarterly Sales of $188.14 Million
www.americanbankingnews.com - February 11 at 2:28 AM
 Analysts Expect Myriad Genetics, Inc. (MYGN) to Announce $0.27 EPS Analysts Expect Myriad Genetics, Inc. (MYGN) to Announce $0.27 EPS
www.americanbankingnews.com - February 9 at 7:14 PM
Myriad Genetics: Analyzing The Qualms Over The Multiple - Seeking AlphaMyriad Genetics: Analyzing The Qualms Over The Multiple - Seeking Alpha
seekingalpha.com - February 9 at 3:22 PM
Myriad Genetics, Inc. (MYGN) to Post FY2018 Earnings of $1.15 Per Share, Gabelli ForecastsMyriad Genetics, Inc. (MYGN) to Post FY2018 Earnings of $1.15 Per Share, Gabelli Forecasts
www.americanbankingnews.com - February 9 at 12:53 PM
Brokers Issue Forecasts for Myriad Genetics, Inc.s Q3 2018 Earnings (MYGN)Brokers Issue Forecasts for Myriad Genetics, Inc.'s Q3 2018 Earnings (MYGN)
www.americanbankingnews.com - February 9 at 11:37 AM
Q3 2018 EPS Estimates for Myriad Genetics, Inc. Increased by Leerink Swann (MYGN)Q3 2018 EPS Estimates for Myriad Genetics, Inc. Increased by Leerink Swann (MYGN)
www.americanbankingnews.com - February 9 at 11:36 AM
BTIG Research Analysts Give Myriad Genetics (MYGN) a $44.00 Price TargetBTIG Research Analysts Give Myriad Genetics (MYGN) a $44.00 Price Target
www.americanbankingnews.com - February 8 at 8:54 PM
Myriad Genetics, Inc. (MYGN) Forecasted to Post Q1 2019 Earnings of $0.32 Per ShareMyriad Genetics, Inc. (MYGN) Forecasted to Post Q1 2019 Earnings of $0.32 Per Share
www.americanbankingnews.com - February 8 at 3:52 PM
Myriads myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited ... - GlobeNewswire (press release)Myriad's myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:16 PM
Myriad Genetics, Inc. Forecasted to Earn FY2018 Earnings of $1.14 Per Share (MYGN)Myriad Genetics, Inc. Forecasted to Earn FY2018 Earnings of $1.14 Per Share (MYGN)
www.americanbankingnews.com - February 8 at 12:50 PM
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2
finance.yahoo.com - February 8 at 5:08 AM
Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic MutationMyriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation
finance.yahoo.com - February 8 at 5:08 AM
Myriad Genetics (MYGN) PT Raised to $28.00 at Morgan StanleyMyriad Genetics (MYGN) PT Raised to $28.00 at Morgan Stanley
www.americanbankingnews.com - February 7 at 12:44 PM
Myriad Genetics Raises FY18 Financial Guidance - Quick FactsMyriad Genetics Raises FY18 Financial Guidance - Quick Facts
www.nasdaq.com - February 7 at 5:24 AM
Myriad tops Street 2Q forecastsMyriad tops Street 2Q forecasts
finance.yahoo.com - February 7 at 5:24 AM
Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial ResultsMyriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results
finance.yahoo.com - February 7 at 5:24 AM
Myriad Genetics (MYGN) Releases FY18 Earnings GuidanceMyriad Genetics (MYGN) Releases FY18 Earnings Guidance
www.americanbankingnews.com - February 6 at 10:02 PM
Myriad Genetics (MYGN) Issues Q3 Earnings GuidanceMyriad Genetics (MYGN) Issues Q3 Earnings Guidance
www.americanbankingnews.com - February 6 at 10:02 PM
Myriad Genetics (MYGN) Releases  Earnings Results, Beats Estimates By $0.07 EPSMyriad Genetics (MYGN) Releases Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - February 6 at 9:44 PM
A Preview Of Myriad Genetics Q2 Earnings - BenzingaA Preview Of Myriad Genetics' Q2 Earnings - Benzinga
www.benzinga.com - February 6 at 3:15 PM
Myriad Genetics, Inc. to Host Earnings CallMyriad Genetics, Inc. to Host Earnings Call
finance.yahoo.com - February 6 at 3:15 PM
A Preview Of Myriad Genetics Q2 EarningsA Preview Of Myriad Genetics' Q2 Earnings
feeds.benzinga.com - February 6 at 1:04 PM
Myriad Genetics, Inc. (MYGN) Receives Average Rating of "Hold" from BrokeragesMyriad Genetics, Inc. (MYGN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 6 at 5:18 AM
Cramer's lightning round: S&P Global's stock is 'nothin' ...Cramer's lightning round: S&P Global's stock is 'nothin' ...
finance.yahoo.com - February 2 at 5:19 AM
Goldman Sachs Models 22% Downside To Myriad GeneticsGoldman Sachs Models 22% Downside To Myriad Genetics
finance.yahoo.com - January 30 at 5:19 AM
Myriad Genetics (MYGN) Earns Sell Rating from Analysts at Goldman Sachs GroupMyriad Genetics (MYGN) Earns Sell Rating from Analysts at Goldman Sachs Group
www.americanbankingnews.com - January 29 at 6:02 PM
Myriad Genetics (MYGN) to Release Quarterly Earnings on MondayMyriad Genetics (MYGN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - January 29 at 3:38 AM
Can Molecular Diagnostics Drive Myriads (MYGN) Q2 Earnings?Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
finance.yahoo.com - January 27 at 5:28 AM
Myriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018 - GlobeNewswire (press release)Myriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018 - GlobeNewswire (press release)
globenewswire.com - January 25 at 3:15 PM
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
finance.yahoo.com - January 25 at 3:15 PM
Interesting MYGN Put And Call Options For March 16thInteresting MYGN Put And Call Options For March 16th
www.nasdaq.com - January 25 at 5:25 AM
$188.75 Million in Sales Expected for Myriad Genetics, Inc. (MYGN) This Quarter$188.75 Million in Sales Expected for Myriad Genetics, Inc. (MYGN) This Quarter
www.americanbankingnews.com - January 25 at 1:40 AM
Myriad Genetics, Inc. Forecasted to Post FY2018 Earnings of $1.11 Per Share (MYGN)Myriad Genetics, Inc. Forecasted to Post FY2018 Earnings of $1.11 Per Share (MYGN)
www.americanbankingnews.com - January 24 at 2:53 PM
Zacks: Brokerages Expect Myriad Genetics, Inc. (MYGN) to Announce $0.24 Earnings Per ShareZacks: Brokerages Expect Myriad Genetics, Inc. (MYGN) to Announce $0.24 Earnings Per Share
www.americanbankingnews.com - January 23 at 9:28 PM
Myriad Applauds New Consensus Statement From International ... - GlobeNewswire (press release)Myriad Applauds New Consensus Statement From International ... - GlobeNewswire (press release)
globenewswire.com - January 23 at 8:09 AM
Myriad Genetics, Inc. (MYGN) VP Sells $1,515,573.50 in StockMyriad Genetics, Inc. (MYGN) VP Sells $1,515,573.50 in Stock
www.americanbankingnews.com - January 22 at 6:36 PM
Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate CancerMyriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer
finance.yahoo.com - January 22 at 3:18 PM
Barclays Raises Myriad Genetics (MYGN) Price Target to $35.00Barclays Raises Myriad Genetics (MYGN) Price Target to $35.00
www.americanbankingnews.com - January 22 at 12:46 PM

SEC Filings

Myriad Genetics (NASDAQ:MYGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Myriad Genetics (NASDAQ:MYGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Myriad Genetics (NASDAQ MYGN) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.